To assess the efficacy and safety of ultra rapid (15 minute) infusion of iron polymaltose to iron deficient patients during general anaesthesia, we performed a prospective, interventional non-randomised study on 99 adult patients with iron deficiency with or without anaemia presenting for surgery under general anaesthesia. Over 15 minutes during the maintenance phase of anaesthesia, patients were given iron polymaltose, 500 mg if not anaemic, or 1,000 mg if anaemic. Haemodynamic stability, immediate or delayed iron-related side-effects and efficacy at six weeks were assessed. The incidence of significant hypotension or the requirement for vasopressor was not different before, during or after the iron infusion. There were no serious intraoperative events (allergic reactions or skin staining). Mean (standard deviation, SD) haemoglobin rose from 121 (14) g/l preoperatively to 131 (12) g/l at six weeks (P <0.001). Mean (SD) ferritin rose from 17 (12) μg/l to 110 (83) μg/l by six weeks (P <0.001). At six weeks only four out of 64 contactable patients (6.25%) had a ferritin of <30 μg/l. The incidence of immediate or delayed side-effects was similar to patients undergoing outpatient iron polymaltose infusions and reflective of a post-surgical population. We conclude that up to 1,000 mg of iron polymaltose can be given over 15 minutes without significant haemodynamic compromise to selected patients undergoing general anaesthesia. Iron polymaltose administered in this way appears efficacious in treating iron deficiency.
Iron deficiency and iron deficiency anaemia are common in surgical patients 1 . They are associated with fatigue, decreased productivity, decreased aerobic capacity, increased blood transfusions and increased surgical complications [1] [2] [3] . Iron polymaltose (iron dextrin) is an intravenous iron preparation that has been used in Australia since the 1960s. It is a safe and effective method of correcting iron deficiency in those intolerant of oral iron or when more rapid correction is desirable 4 .
The product information for iron polymaltose recommends that infusions are administered over a period of five hours 5 . Long infusion times increase administration costs and are inconvenient for patients. Iron carboxymaltose is a preparation which can be given over 15 minutes, but is up to ten times more expensive than iron polymaltose 6 . Informal discussion with anaesthetists across Australia and New Zealand revealed that some administer iron polymaltose over short periods of time (5 to 30 minutes) during general anaesthesia, with no adverse effects noted. In order to assess the safety and efficacy of this practice, we conducted a prospective, non-randomised study of an ultra rapid (15 minute) administration of iron polymaltose during general anaesthesia.
Methods
Prior to commencement, we obtained Ethics Committee approval from both the South Metropolitan Area Health Service (12/201) and the Women's and Newborn Health Service (2013012EW) in Perth, Western Australia and registered the trial protocol with the Australian New Zealand Clinical Trials Registry (ACTRN12613000356763).
This prospective, non-blinded, non-randomised interventional study was conducted at two hospitals in Western Australia over a 30-month period (ending in December 2015). Adult participants presenting for surgery under general anaesthesia with iron deficiency (ferritin <30 μg/l), or iron deficiency anaemia (female haemoglobin [Hb] <120 g/l, male Hb <130 g/l and ferritin <100 μg/l) were considered eligible. Our study population reflects opportunistic sampling of patients with iron deficiency presenting for surgery at the study hospitals. Many of the patients were having surgery for menorrhagia. After providing written informed consent, iron deficient patients were prescribed 500 mg of intravenous iron polymaltose, and patients with iron deficiency anaemia prescribed 1,000 mg, for administration during their general anaesthetic.
Patients were excluded from participation if they were pregnant, had clinically significant liver or kidney disease, active infection, chronic polyarthritis or a history of intolerance to iron polymaltose.
All aspects of the anaesthesia were left to the discretion of the treating anaesthetist. The iron infusion was commenced during the maintenance phase of the anaesthetic; at least 15 minutes after induction. The iron polymaltose was diluted with normal saline to give a final volume of 100 ml and infused over 15 minutes (33 or 67 mg of iron/minute). No test dose was given.
Baseline demographic, laboratory data (haemoglobin and ferritin), type of surgery and whether it was indicated for bleeding were recorded preoperatively. Haemodynamic observations including heart rate, systolic blood pressure (SBP) and vasopressor requirements, were recorded every 2.5 minutes for a total of 40 minutes: from induction for 15 minutes; during the iron infusion for 15 minutes and for a further 10 minutes after the infusion. Allergic events such as anaphylaxis, bronchospasm and rash were specifically sought. At the time of recruitment, patients were given information regarding the immediate and delayed adverse effects of iron administration. Patients were contacted by telephone at two weeks to assess potential iron-related side-effects, specifically nausea, headache, myalgia and abdominal pain. They were instructed to have a repeat full blood count and iron studies at six weeks.
Sample size was calculated using the Vanderbilt sample size calculator (biostat.mc.vanderbilt.edu/PowerSampleSize). The proportion of patients who develop significant hypotension (SBP <80 mmHg) post-induction was thought to be 20%. A higher rate of hypotension with the iron infusion was thought to be clinically significant. A sample size of 85 was calculated, with an alpha value of 0.05 and power of 0.85. Allowing for dropouts and difficulties with follow-up, the aim was to recruit 100 patients.
Data were entered into a Microsoft spreadsheet and analysed using SPSS version 23. The primary endpoint for this study was intraoperative haemodynamic instability during and after iron infusion as defined by either significant hypotension (SBP <80 mmHg) or an increase in vasopressor requirement compared to the induction phase of anaesthesia. Secondary endpoints assessed were the change in ferritin and haemoglobin at six weeks and the incidence of postoperative side-effects attributable to the iron infusion. Normally distributed data (blood pressure, haemoglobin and ferritin) are presented as mean (standard deviation [SD]) and compared using paired t-tests. Fisher's exact test was used to compare vasopressor requirements following induction, during and after the iron infusion. A P-value of <0.05 was considered statistically significant. All side-effects were grouped by system and severity (mild/ moderate/severe) and their likely relationship to the iron infusion assigned by consensus of the investigators.
Results
In total, 100 patients were recruited into the study, with 99 patients receiving the iron polymaltose infusion and 98 included in the statistical analysis. The patient who did not get the iron infusion had a change of anaesthetic technique to regional after recruitment. The other patient not analysed was excluded as their ferritin (229 μg/l) was higher than the inclusion criteria of 100 μg/l despite being anaemic. The demographic characteristics of the study population are presented in Table 1 . All bar six participants were having gynaecological surgery and were recruited from the state's tertiary women's hospital. Seventy-one percent of the patients included in the study were having surgery to treat bleeding.
Thirty-six patients had iron deficiency anaemia (Hb <120 g/l, ferritin <30 μg/l) and three further patients were anaemic with a ferritin between 30 and 100 μg/l; 59 patients had isolated iron deficiency (Hb >120 g/l, ferritin <30 μg/l).
With regard to the primary outcome, there was no difference in the proportion of patients with significant hypotension (SBP <80 mmHg) before or after the iron infusion was commenced; with 20 patients (20.4 %) becoming hypotensive within the first 15 minutes after induction of general anaesthesia and 17 patients (17.3%) during the 25 minutes after starting the iron infusion (P=0.715), (Figure 1 ). Mean (SD) SBP during and after the iron infusion, 106 (18) mmHg, was marginally higher than the postinduction (preinfusion) SBP of 103 (19) mmHg (P=0.001). The number of patients who required vasopressor support at any timepoint is presented in Figure 2 and the proportion was unchanged before (6.3%) and after (6.4%) the iron infusion (P=0.916). There was a drop in SBP following induction from 131 (20) mmHg to 107 (22) mmHg (P <0.001), which was significant, and the SBP remained lower than the starting SBP throughout the study period. There were no intraoperative allergic events, and no evidence of tissue extravasation or skin staining.
We compared two time periods; the first 15 minutes after induction of anaesthesia and the following 25 minute period during and after completion of the iron polymaltose infusion. We did not detect any clinically significant difference in heart rate, blood pressure, or use of vasopressor medications. There were no arrhythmias, respiratory problems (hypoxia, wheeze), allergic phenomena or any other serious adverse events recorded.
Of the 98 patients included in the analysis, 84 were contactable two weeks postoperatively. Side-effects reported in the two weeks following surgery included; nausea 40%, headache 36%, abdominal pain 42%, and myalgia 43%. Moderate symptoms were present in 28.6%, and severe symptoms in 10.7%. Postoperative infections were reported by eight patients (9.5%); four urinary tract infections, three abdominal wound infections and one sinusitis.
Preoperative haemoglobin and ferritin values were available in all 98 patients, six-week haemoglobin in 67 patients and six-week ferritin in 64 patients. Mean (SD) haemoglobin rose from 121 (14) g/l preoperatively to 131 (12) g/l at six weeks (P <0.001). In the 29 patients with a recorded six-week and a nadir haemoglobin (defined as a haemoglobin in the first postoperative week), mean haemoglobin rise was 26 g/l from the nadir of 102 (18) g/l. Mean ferritin rose from 17 (12) μg/l to 110 (83) μg/l by six weeks (P <0.001). At six weeks only four out of 64 patients (6.25%) had a ferritin of <30 μg/l. 
Discussion
The most important finding of this study is the demonstration of the relative haemodynamic stability observed in patients during an infusion of iron polymaltose at rates of up to 67 mg/minute. The incidence of significant hypotension and the requirement for vasopressor in patients undergoing general anaesthesia was not different before, during or after the iron infusion. This is reassuring as one of the primary concerns with fast infusion rates of iron preparations is hypotension 7 .
There are publications supporting the use of more rapid infusions over one to two hours 8, 9 . It is unclear whether more rapid infusions are associated with an increased rate of adverse events [9] [10] [11] . One study reported no difference in the incidence of adverse effects between a two-hour and four-hour infusion 9 .
The incidence of side-effects in our study (nausea, headache, abdominal pain, myalgia, and postoperative infection) appears to be similar to those found in patients undergoing outpatient iron polymaltose infusions [8] [9] [10] and patients after gynaecological surgery 12 . We found an overall postoperative infection incidence of 9.5%, no greater than reported findings in similar surgical cohorts 13, 14 .
We also demonstrate the efficacy of iron polymaltose when administered to this patient group at the time of their surgery. The observed rise in haemoglobin, ferritin and the correction of iron deficiency in 94% of patients (63 of the 67 patients who had a postoperative haemoglobin measured) suggests that intravenous iron polymaltose, when administered rapidly under general anaesthesia, is efficacious.
There is significant evidence that patients presenting for surgery with preoperative anaemia have worse postoperative outcomes and the National Blood Authority of Australia perioperative patient blood management guidelines 3 recommend that it is best practice to identify and correct anaemia in these patients prior to surgery. At present, when anaemic patients present for surgery there has to be a clinical judgement of the benefits of delaying surgery to correct anaemia versus proceeding. The National Blood Authority perioperative guidelines suggest the administration of 150 mg of intravenous iron per 10 g/l haemoglobin drop in populations similar to this one studied 3 . There are many potential benefits from the perioperative administration of iron polymaltose to iron deficient patients which include; increased aerobic capacity, decreased fatigue, quicker recovery, avoidance of transfusion, fewer postoperative complications and avoidance of the adverse effects of postoperative oral iron 15 . Potential disadvantages could include possible increased surgical infection rates 16 or increased postoperative adverse effects (nausea, headache, pain, myalgia).
There are three intravenous iron preparations currently licenced for use in Australia 17 ; iron polymaltose, iron sucrose and iron carboxymaltose. Iron carboxymaltose and iron sucrose are licenced to be given over short time periods (two to 30 minutes) and are also suitable for rapid infusion in theatre. They both have disadvantages: iron sucrose can only be given as a 200 to 300 mg dose, and iron carboxymaltose is significantly more expensive. The current dispensed price for a 1,000 mg dose of iron carboxymaltose is A$306.81 versus A$28.31 for iron polymaltose 5,6 .
The weaknesses of our study relate to the small sample size, limiting the ability to detect rare effects and the lack of a placebo control in this haemodynamic safety study. There were no arrhythmias, respiratory problems (hypoxia, wheeze), allergic phenomena or any other serious adverse events recorded. The point estimate for the incidence of these events from this study is zero. However, the upper boundary of the 95% confidence interval for these estimates is 3% 18 .
Without a placebo control, this study was both feasible and ethically acceptable (the current practice of many of the anaesthetists was to give iron polymaltose in this patient population) but limited when considering postoperative outcomes. In reporting the two week follow-up incidence of nausea, headache, abdominal pain, myalgia, and postoperative infection, we are unable to assign causality to the iron infusion, anaesthesia, surgery or underlying medical conditions. Similarly, the demonstration of clinically significant rises in both haemoglobin and ferritin at six weeks is consistent with the expected effects of intravenous iron in iron deficient individuals 19 , but without a control arm we cannot make any conclusions as to how these results would compare with either no treatment or a postoperative course of oral iron 15 .
A further limitation of our study relates to the nature of the study population. The typical patient was relatively young, American Society of Anesthesiologists physical status 2, having American Heart Association/American College of Cardiology classified intermediate risk surgery 20 for the management of gynaecological bleeding 20 . We remain cautious about the extrapolation of these results to older or sicker patients.
We designed this study as some anaesthetists were already using iron polymaltose, administered rapidly during surgery to correct iron deficiency and anaemia in this patient population. The most common adverse effects seen during iron infusion, such as headache, myalgia, nausea, metallic taste, or cannula site pain are irrelevant to patients under general anaesthesia. A common observation of the investigators recruiting these patients was the desire of many who had previously had an iron infusion awake, to have a rapid correction of their iron deficiency under anaesthesia.
The results of this study suggest areas for future investigation. We believe that it is worth investigating the safety and tolerability of rapid infusion times for iron polymaltose in other settings; outpatient iron infusion clinics, patients having regional anaesthesia and patients undergoing endoscopy for investigation of iron deficiency. It would be of value to compare iron polymaltose with iron carboxymaltose, as well using intravenous iron in operative situations with major blood loss, assessing short-and longterm outcomes.
Conclusion
This study provides preliminary safety and efficacy data about the ultra rapid administration of iron polymaltose in patients undergoing general anaesthesia. We are cautiously reassured that in this relatively well population there is no signal that this infusion speed is associated with haemodynamic compromise. Future studies are indicated to assess the longer-term benefits of perioperative administration of iron polymaltose, patient preferences, safety in sicker patient populations and to investigate the safety of ultra rapid iron polymaltose infusions in settings outside the operating theatre.
